STOCK TITAN
  1. Home
  2. News
  3. ITRM

Iterum Therapeutics Plc - ITRM STOCK NEWS

Welcome to our dedicated news page for Iterum Therapeutics Plc (Ticker: ITRM), a resource for investors and traders seeking the latest updates and insights on Iterum Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iterum Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iterum Therapeutics Plc's position in the market.

News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Iterum Therapeutics plc (Nasdaq: ITRM) reported positive topline data from its REASSURE trial for the treatment of adult women with uncomplicated urinary tract infections (uUTIs). They plan to resubmit the NDA early in Q2 2024. The company's cash runway extends into 2025, including potential FDA approval in early Q4 2024. Iterum is engaged in a strategic process to sell, license, or dispose of rights to sulopenem to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
earnings
-
News
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Rhea-AI Summary
Iterum Therapeutics plc (ITRM) to Release Q4 and Full Year 2023 Financial Results, Host Conference Call on March 28, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences earnings
-
News
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
Rhea-AI Summary
Iterum Therapeutics plc (ITRM) to participate in H.C. Wainwright @Home Fireside Chat to discuss oral sulopenem program for UTIs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
News
Iterum Therapeutics Provides Business Update
Rhea-AI Summary
Iterum Therapeutics plc (ITRM) plans to resubmit its NDA for oral sulopenem to the FDA in the first half of Q2 2024, with an extended cash runway into 2025. Positive top-line results from the REASSURE trial were announced in January 2024, leading to a strategic evaluation of selling or licensing sulopenem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.79%
Tags
none
-
News
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Rhea-AI Summary
Iterum Therapeutics plc announced positive results from the REASSURE Phase 3 clinical trial comparing oral sulopenem to oral Augmentin® in treating uUTIs. The results showed that sulopenem was non-inferior to Augmentin®, with a statistically significant superiority of sulopenem. Iterum plans to resubmit the NDA for sulopenem in Q2 2024 and is focusing on a strategic process to sell, license, or dispose of its rights to sulopenem to maximize value for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.73%
Tags
clinical trial
-
News
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
Rhea-AI Summary
Iterum Therapeutics plc (Nasdaq: ITRM) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Company was previously notified that it was not in compliance because its ordinary shares failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. Iterum was provided with 180 calendar days to regain compliance and successfully met the requirement on November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
News
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Iterum Therapeutics plc (Nasdaq: ITRM) reported financial results for Q3 2023, completed enrollment of 2,229 patients in REASSURE trial for uUTI treatment, expects top-line data in Q1 2024, plans NDA resubmission in Q2 2024. New patents granted in Korea and Australia. Cash, cash equivalents, and short-term investments at $35.9 million as of September 30, 2023. R&D expenses increased to $14.9 million, G&A expenses decreased to $1.8 million. Net loss for Q3 2023 was $3.9 million. Conference call scheduled for November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
earnings
-
News
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
Iterum Therapeutics plc (Nasdaq: ITRM) will release its third quarter 2023 financial results on Tuesday, November 14, 2023, before the open of the U.S. financial markets. A conference call will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
earnings
-
News
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Rhea-AI Summary
Iterum Therapeutics completes patient enrollment in its REASSURE clinical trial, expects topline data in Q1 2024 and plans to resubmit NDA in Q2 2024 for oral sulopenem for the treatment of uUTIs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
clinical trial
News
Iterum Therapeutics to Present Data at IDWeek 2023
Rhea-AI Summary
Iterum Therapeutics announces presentation of three posters at IDWeek 2023 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
conferences
Stock ITRM logo
Iterum Therapeutics Plc

Nasdaq:ITRM

ITRM Rankings

#5049 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ITRM Stock Data

25.95M
15.34M
1.52%
7.57%
7.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About ITRM

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.